Analysis of Protein Biomarkers From Hospitalized COVID-19 Patients Reveals Severity-Specific Signatures and Two Distinct Latent Profiles With Differential Responses to Corticosteroids*

Author:

Verhoef Philip A.12,Spicer Alexandra B.3,Lopez-Espina Carlos4,Bhargava Akhil4,Schmalz Lee4,Sims Matthew D.5,Palagiri Ashok V.6,Iyer Karthik V.7,Crisp Matthew J.7,Halalau Alexandra5,Maddens Nicholas5,Gosai Falgun8,Syed Anwaruddin8,Azad Saleem7,Espinosa Aimee5,Davila Francisco5,Davila Hugo5,Evans Neil R.8,Smith Scott5,Reddy Bobby4,Sinha Pratik9,Churpek Matthew M.3

Affiliation:

1. Hawaii Permanente Medical Group, Honolulu, HI.

2. Department of Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI.

3. Department of Medicine, University of Wisconsin-Madison, Madison, WI.

4. Prenosis Inc., Chicago, IL.

5. Beaumont Health System, Royal Oak, MI.

6. Mercy Hospital, St. Louis, MO.

7. Mercy Hospital, Jefferson, MO.

8. OSF Saint Francis Medical Center, Peoria, IL.

9. Department of Anesthesiology, Washington University School of Medicine, St. Louis, MO.

Abstract

OBJECTIVES: To identify and validate novel COVID-19 subphenotypes with potential heterogenous treatment effects (HTEs) using electronic health record (EHR) data and 33 unique biomarkers. DESIGN: Retrospective cohort study of adults presenting for acute care, with analysis of biomarkers from residual blood collected during routine clinical care. Latent profile analysis (LPA) of biomarker and EHR data identified subphenotypes of COVID-19 inpatients, which were validated using a separate cohort of patients. HTE for glucocorticoid use among subphenotypes was evaluated using both an adjusted logistic regression model and propensity matching analysis for in-hospital mortality. SETTING: Emergency departments from four medical centers. PATIENTS: Patients diagnosed with COVID-19 based on International Classification of Diseases, 10th Revision codes and laboratory test results. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Biomarker levels generally paralleled illness severity, with higher levels among more severely ill patients. LPA of 522 COVID-19 inpatients from three sites identified two profiles: profile 1 (n = 332), with higher levels of albumin and bicarbonate, and profile 2 (n = 190), with higher inflammatory markers. Profile 2 patients had higher median length of stay (7.4 vs 4.1 d; p < 0.001) and in-hospital mortality compared with profile 1 patients (25.8% vs 4.8%; p < 0.001). These were validated in a separate, single-site cohort (n = 192), which demonstrated similar outcome differences. HTE was observed (p = 0.03), with glucocorticoid treatment associated with increased mortality for profile 1 patients (odds ratio = 4.54). CONCLUSIONS: In this multicenter study combining EHR data with research biomarker analysis of patients with COVID-19, we identified novel profiles with divergent clinical outcomes and differential treatment responses.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Critical Care and Intensive Care Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3